Procurement optimisation in the pharmaceutical industry
For years, extending the supply chain for active pharmaceutical ingredients to Asia was seen as a panacea against ever-increasing cost pressure. Since the beginning of the Corona virus pandemic, a rethink has set in: There is now a consensus that the active ingredients for medicines needed en masse should not be produced exclusively in India or China.
The temporarily limited availability of central active ingredients such as painkillers or antibiotics shows very clearly the risk that arises when precursors are only sourced from one region or even from a single supplier. Since medicines are not consumer goods but part of the provision of public services, permanent production and delivery capability must be ensured.
This does not mean that the entire supply chain must now be located in Europe, which would not even be possible given current capacities. But the move away from single sourcing is a necessary measure in view of supply risks. Selecting European suppliers strengthens the resilience of the entire system.
In order to diversify or re-regionalise supply chains, strategic procurement is indispensable. Our experts analyse your company’s existing supply chain and support you in establishing and qualifying local suppliers.
Define and implement sustainability goals
Cost reduction in Indirect Spend
More on indirect spend